Treatment of HBe antigen-positive chronic hepatitis B

Seminars in Liver Disease

Volumn 23, Issue 1, 2003, Pages 69-79

  Heathcote, Jenny ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

HBeAg positive hepatitis; IFN; Lamivudine; Lamivudine resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PLACEBO; PREDNISOLONE; VIRUS DNA;

CHILL; CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FANCONI ANEMIA; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; MALAISE; MONOTHERAPY; MORBIDITY; MYALGIA; NEUROTOXICITY; PHOSPHATURIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SEPSIS; SEROCONVERSION; SIDE EFFECT; SURVIVAL; TOXICITY; TREATMENT OUTCOME;

EID: 0037328005     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37588     Document Type: Review

References (63)

1. Scullard GH, Andres LL, Greenberg HB, et al. Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside. Hepatology 1981;1:228-232
2. Lok A, Novick D, Karayiannis P, et al. A randomized study of the effects of adenine arabinoside 5′-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology 1985;5:1132-1138
3. Hsu Y, Chien R, Yeh C, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-1527
4. Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002;36:543-546
5. Wong D, Cheung A, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993;119:312-323
6. Wong D, Yim C, Nayor D, et al. Interferon alfa treatment of chronic hepatitis. B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995;108:165-171
7. Perrillo R, Schiff E, Davis D, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;35:295-301
8. Lin S, Sheen I, Chien R, Chu C, Liaw YF. Long term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;23:971-975
9. Yuen M, Hui C, Cheng C, et al. Long term follow up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-145
10. Lau D, Everhart J, Kleiner D, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-1667
11. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S, and the European Concerted Action on Viral Hepatitis (EUROHEP). Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997;26:1338-1342
12. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427
13. Hoofnagle JH, Di Bisgalie AM, Laggoner JH, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to hepatitis B. Gastroenterology 1993;104:1116-1121
14. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-1838
15. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-763
16. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B and the response to interferon therapy. Hepatology 2000;33:998-1002
17. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756-1762
18. Janssen H, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. Hepatology 1999;30:238-243
19. Carreno V, Marcellini P, Hadziyannis S, et al. Retreatment of chronic hepatitis B e antigen positive patients with recombinant interferon alfa 2a. Hepatology 1999;29:277-282
20. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study. Gastroenterology 1997;113:1258-1263
21. Lai C, Chien R, Leung N, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68
22. Dienstag J, Schiff E, Wright T, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
23. Schalm S, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000;46:562-568
24. Liaw YF, Leung N, Chang T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180
25. Leung N, Lai C, Chang T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1531
26. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194
27. Chien R, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-774
28. Lewin SR, Ribeiro RM, Walters T, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012-1020
29. Ahmed S, Tavan D, Pichoud C, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088
30. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antiviral Chem Chemother 2000;12:67-71
31. Yuen M, Sablon E, Hui C, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791
32. Buti M, Cotrina M, Valdes A, et al. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002;36:445-446
33. Liu C, Chen P, Lai M, Kao J, Chen DS. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001;34:583-589
34. Liaw YF, Chien R, Yeh C, Tsai S, Chu C. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572
35. Bonacini M, Kurz A, Locarnini S, et al. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002;122:244-250
36. Wong VWS, Chan H, Wong M, Leung N. Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B? J Hepatol 2002;36:177
37. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. To continue or not continue lamivudine therapy after emergence of YMDD mutations. Gastroenterology 2002;122:7. Abst 88
38. Ono-Nita S, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103:1635-1640
39. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134
40. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses Lam-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. J Hepatol 2002;36:6. Abst 13
41. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-313
42. Yeh C, Chien R, Chu C, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-1326
43. Kim JW, Lee HS, Woo GH, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. CID 2001;33:403-405
44. Marcellin P, Chang TT, Lim SG, et al. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. Hepatology 2001;34:340A. Abst 674
45. Yang H, Westland CE, Delaney WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-473
46. Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001;149:436-440
47. Barbaro G, Zechini F, Pellicelli A, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001;35:406-411
48. Serfaty L, Thabut D, Zoulim F, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573-577
49. Lau G, Tsiang M, Hou J, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese patients: a viral dynamics study. Hepatology 2000;32:394-399
50. van Nunen A, Janssen H, Wolters L, et al. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? Antiviral Res 2001;52:139-146
51. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology 2000;32:430-432
52. Liaw YF, Tsai S, Chien R, Yeh C, Chu C. Prednisolone priming enhances TH1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000;32:604-609
53. Villeneuve JP, Willems B. Treatment of chronic hepatitis B with interferon: long term follow-up. Can J Gastroenterol 1996;10:21-25
54. Lok A, Chung H, Liu V, Ma O. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-1838
55. Song B, Suh D, Lee H, Chung Y, Lee Y. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806
56. Brook M, Petrovic L, McDonald J, Scheuer P, Thomas H. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection. J Hepatol 1989;8:218-225
57. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-748
58. Rehermann B, Lau D, Hoofnagle JH, et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996;97:1655-1665
59. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975
60. Buti M, Sanchez F, Cotrina M, et al. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. J Infect Dis 2001;183:1277-1280
61. Han D, Kim T, Park S, et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001;71:387-394
62. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62
63. Liao C, Lee C, Wu H, et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Hepatol 2002;116:166-169